𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection

✍ Scribed by Ponni Perumalswami; David E. Kleiner; Glen Lutchman; Theo Heller; Brian Borg; Yoon Park; T. Jake Liang; Jay H. Hoofnagle; Marc G. Ghany


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
218 KB
Volume
43
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


Hepatic steatosis is common in patients with chronic hepatitis C (CHC) and is reported to be a risk factor for progression of fibrosis. The aims of this study were to evaluate the interactions between hepatic steatosis and fibrosis in a well-defined cohort of patients with CHC. The computerized pathology database at the National Institutes of Health Clinical Center was searched for patients with CHC who had undergone liver biopsy between 1980 and 2003. Biopsies were scored for necroinflammation using a modified histology activity index, fibrosis using the Ishak system, and steatosis as either none (<5% of cells), mild (5%-25%), or moderate-to-severe (>25%). Four hundred ninety-four patients were identified. The mean age was 44 ؎ 9.8 years; 60% were male, 80% Caucasian, and 65% were infected with genotype 1. Steatosis was mild in 31% and moderate to severe in 9% of patients. In univariate analysis, steatosis was associated with increased age, body weight, body mass index (BMI), alanine aminotransferase (ALT) levels, histological necroinflammatory activity, and fibrosis. However, in multivariate analysis, steatosis was associated only with increased age, BMI, and ALT levels and not with fibrosis. One hundred thirty-six patients had 2 liver biopsies separated by 0.5 to 17 years. Worsening of fibrosis occurred in 40% of patients and correlated independently with increasing age, periportal necroinflammation, and ALT elevations but not with steatosis. In conclusion, in this cohort of patients with CHC, steatosis was associated with older age, higher BMI, and higher serum ALT levels but not with the presence of or subsequent progression of fibrosis. (HEPATOLOGY 2006;43: 780-787.) C hronic hepatitis C is a major cause of cirrhosis,


πŸ“œ SIMILAR VOLUMES


Impact of steatosis on progression of fi
✍ Laetitia Fartoux; Olivier ChazouillΓ¨res; Dominique Wendum; Raoul Poupon; Lawrenc πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 119 KB πŸ‘ 1 views

In patients with mild hepatitis C, the usefulness of antiviral therapy is subject of debate, as a low risk for progression of fibrosis is assumed. Several studies have shown that steatosis is a strong and independent predictor of the severity as well as the progression of fibrosis in chronic hepatit

Cryoglobulinemia is associated with stea
✍ David Saadoun; Tarik Asselah; Mathieu Resche-Rigon; FrΓ©dΓ©ric Charlotte; Pierre B πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 125 KB πŸ‘ 1 views

The relationship between cryoglobulin and severity of liver lesions is debated. No study has focused on the relationship between cryoglobulin, liver steatosis, and fibrosis. The aim of this study was to determine the relationship between cryoglobulins and liver lesions (necroinflammation, fibrosis,